Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Advanced Oncotherapy | VolitionRx | Scancell Holdings Plc | Faron Pharmaceuticals Oy | Highlands Natural Resources Plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.


Register


Advanced Oncotherapy

RSS Portfolio

Advanced-Oncotherapy-logo.png


Advanced Oncotherapy plc is a UK-based company focused on delivering a cost-effective proton-based radiotherapy solution called LIGHT. Based on ground-breaking technology developed and tested at world renowned CERN in Switzerland, the LIGHT system delivers an integrated proton radiotherapy system to treat cancer. The uniqueness of LIGHT means that it is possible to treat patients in the centre of any major city in the world at an affordable price.

EPIC: AVO
Market: AIM
52-week High/Low: 174.50p / 4.88p
Market Cap: 53.64M


View full company profile

Faron Pharmaceuticals Oy

RSS Portfolio

fr.png


Faron Pharmaceuticals is a clinical stage drug discovery and development company based in Turku, Finland. Faron has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. Implementing the strategy of creating a novel treatment for significant unmet medical needs, Faron has now entered into a pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). Currently there is no available drug treatment for ARDS, an orphan lung disease coupled with a reported mortality rate of approximately 30 to 45%. Although ARDS is not common, there are about 170 000 patients annually in Europe and nearly 200 000 in the US.

EPIC: FARN
Market: AIM
52-week High/Low: 271.00p / 245.00p
Market Cap: 71.04M


View full company profile

Highlands Natural Resources Plc

RSS Portfolio

highlands_1.png


Highlands Natural Resources plc is a UK registered investment vehicle focused on acquiring oil and gas assets which are commercial at current oil prices.  The Company, established in November 2014 by highly experienced oil and gas and financial professionals, listed on the London Stock Exchange in March 2015

EPIC: HNR
Market: LSE
52-week High/Low: 76.75p / 10.63p
Market Cap: 18.32M


View full company profile

Scancell Holdings Plc

RSS Portfolio

scancell.gif


Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

Scancell is traded in the ISDX Exchange HERE

EPIC: SCLP
Market: AIM
52-week High/Low: 21.50p / 13.00p
Market Cap: 37.27M


View full company profile

VolitionRx

RSS Portfolio

volition-logo.png


VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

EPIC: VNRX
Market: NYSE
52-week High/Low: $5.40 / $3.05
Market Cap: $124.19M


View full company profile

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.